ASDERA is developing the first drug with the potential to change the course of neuro-degenerative diseases, including Alzheimer's, Parkinson's and Huntington's disease as well as amyotrophic lateral sclerosis (ALS).
There are currently no drugs with a lasting effect for people with AD or PD. The patented ASDERA approach identified the mechanism under lying "deranged" endocytosis and a drug to "rerange" it.
The proposed mechanism of action is down-regulation of endocytosis (of APP, α-synuclein, ...) to prevent aging lysosomes from interfering with autophagy and the proposed drug is a derivative of HP-α-cyclodextrin to down-regulates the activity of the PI-cycle, which controls endocytosis.
(click on either of the icons in the lower left corner to download a flyer pdf (top) or a ppt or pdf deck (bottom) with more details)